首页> 外文期刊>Photodermatology, photoimmunology and photomedicine >5-aminolaevulinic acid patch-photodynamic therapy in the treatment of actinic cheilitis
【24h】

5-aminolaevulinic acid patch-photodynamic therapy in the treatment of actinic cheilitis

机译:5-氨基乙酰硫酸贴片 - 光动力学治疗在治疗光化杂质炎

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background: Actinic cheilitis (AC) is a common disease caused by chronic ultraviolet exposure.Objective: Alacare is a self-adhesive, skin coloured 5-aminolaevulinic acid (ALA) patch that has been developed for the treatment of mild to moderate actinic keratosis (AK). Considering the good results in the treatment of AK, the standardized delivery of ALA and the simple application Alacare patch- photodynamic therapy (PDT) appears as an interesting treatment option for AC.Methods: We retrospectively assessed the efficacy, tolerability and cosmetic outcome of Alacare patch-PDT in eleven patients with AC. After occlusion with the Alacare patches for 4 hours, the AC lesions were illuminated with narrowband red iight and a dose of 37 J/cm~2. All patients were clinically assessed for efficacy, side effects and cosmetic outcome at 3,6, 9 and 12 months after treatment. Results: Complete clinical response at the 3-month follow-up was achieved in eight of 11 patients (72,7%) and 12 of 15 AC lesions (80,0%), respectively. Up to the final 12-month follow-up, a recurrence was observed in two lesions. The complete clinical cure rate at 1 year after Alacare patch-PDT, thus, was 66,6% (10/15 lesions). The cosmetic outcome of the treatment was excellent in all cases.Conclusion: Alacare patch-PDT was found to have substantial efficacy in the treatment of mild to moderate AC. Given its ease of use, absence of long-term side effects and the excellent cosmetic results Alacare patch-PDT might be considered as a promising new treatment option for the management of AC.
机译:背景:光化杂质炎(AC)是慢性紫外线曝光引起的常见疾病。目的:Alacare是一种自粘,皮肤有色5-氨基乙酰丙酸(ALA)贴片,用于治疗轻度至中度光碱角瘤( AK)。考虑到AK的治疗方法的良好结果,ALA的标准化递送和简单的应用Alacare Patch-Photoction-Therapy(PDT)表现为AC.Methods的一个有趣的治疗选择:我们回顾性评估了Alacare的疗效,耐受性和化妆品结果在11名AC患者中的补丁PDT。在闭塞闭塞4小时后,用窄带红色的抗体和37J / cm〜2的剂量照射交流病变。在治疗后3,6,9和12个月,所有患者临床评估疗效,副作用和化妆品结果。结果:分别在11名患者中的八个(72,7%)和15名AC病变(80,0%)中实现了3个月随访的完整临床反应。最终的12个月随访后,在两个病变中观察到复发。因此,Alacare Patch-PDT的1年后的完整临床固化率为66,6%(10/15病变)。治疗的化妆品结果在所有情况下都是优异的。结论:发现Alacare Patch-PDT在治疗轻度至中度Ac的处理中具有大量功效。鉴于其易用性,缺乏长期副作用和优异的化妆品结果Alacare Patch-PDT可能被认为是管理交流管理的有希望的新治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号